Min. Order : 1 Kilogram
100-999 Kilograms
>=1000 Kilograms

GMP factory Supply CP/ BP/ EP9 standard Gliclazide powder CAS 21187-98-4 with lowest price

Trade Assurance
Built-in order protection service in alibaba.com
Product quality
On-time shipment
More on shipping and other trade services.

Quick Details

Port: China main port
Payment Terms: L/C,D/A,D/P,T/T,Western Union,MoneyGram
Supply Ability: 2000 Kilogram/Kilograms per Month
Other Names: Nordialex
Place of Origin: China
Molecular Weight: 323.410
Grade Standard: Medicine Grade
Product Name: Gliclazide powder
Purity: 99%
Shelf life: 2 Years
Grade: Phamaceutical Grade
Model Number: /
Appearance: White Crystalline Powder
CAS No.: 21187-98-4
Brand Name: Virgin
Type: antihyperglycemic agent
Test Method: HPLC
CAS: 21187-98-4
MF: C15H21N3O3S
Molecular Formula: C15H21N3O3S
Application: Pharmaceutical Raw Intermediates
Certificate: GMP/ISO9001
Packaging Detail: 1kg/bag (Inner: plastic bag .outer: Aluminum foil bag ); 5kg/carton (Inner: Double plastic bags. Outer: Carton); 10kg/carton (Inner: Double plastic bags. Outer: Carton); 25kg/drum (Inner: Double plastic bags. Outer: Fiber drum); Others: According to customer demand. Cool and dry place, keep away from strong light
Package Preview: https://sc04.alicdn.com/kf/H8d1fbd9203e64a839e00646f6558296cG.jpg_640x640.jpg
Xi'an Virgin Biological Technology Co., Ltd.
Response Rate
On-time delivery rate
US$ 20,000+
R&D staffs
Visit Store

GMP factory Supply CP/ BP/ EP9 standard  Gliclazide powder CAS 21187-98-4 with lowest price

Product Description


Gliclazide CAS 21187-98-4 Brand: Virgin
MW: 323.41 MSDS: Avaiable
MF : C15H21N3O3S Sample: Avaiable
Category:   Diabetes drug Min order: 10grams
Quality standard : EP7.0/BP2009 Place of Origin:China
Introduction The treatment of type (II) diabetes
Character A white or almost white powder
Applications Pharmaceutical raw materials


Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It has been classified differently according to its drug properties in which based on its chemical structure, gliclazide is considered a first-generation sulfonylurea due to the structural presence of a sulfonamide group able to release a proton and the presence of one aromatic group. On the other hand, based on the pharmacological efficacy, gliclazide is considered a second-generation sulfonylurea which presents a higher potency and a shorter half-life. Gliclazide belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Gliclazide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Gliclazide is extensively metabolized by the liver; its metabolites are excreted in both urine (60-70%) and feces (10-20%).




Image 12.jpg